Objective: To explore the relation of MetS and urolithiasis in our center. Material & Methods: This is a prospective study of all patients diagnosed with urolithiasis in Kardinah Hospital, Tegal, from April to June 2018, who were screened for metabolic syndrome criteria. The data was collected from the medical record and analyzed with SPSS ver. 23. Results: We included 71 cases of urinary tract stone in our center. 8.4% of the patients didn’t undergo definitive therapy for stones caused by patients’ preferences or the surgery being postponed with various reasons. The patient's mean age is 54.7 ± 11.24, with a male to female ratio 2.4:1. The average BMI is 20.9 ± 2.3 kg/m2. Most of the stones are found in kidney (38.0%) and bladder (26.8%). The average blood pressure is 127.2 ± 7.96 mmHg for systolic pressure and 81.6 ± 5.77 mmHg for diastolic pressure. The average values of lipid profile include total cholesterol, high- and low-density lipoprotein, and triglyceride were 177.0 ± 35.92, 52.0 (27-96), 107.3 ± 37.58 and 131 (50-406), respectively. The mean of patient’s blood glucose level is 122 mg/dL, and the highest level is 203 mg/dL. Conclusion: Not all of the MetS traits found in our patients in Kardinah Hospital. The HDL level is the only variable that shown abnormal level and it could be included into one of the MetS criteria of diagnosis. Thus, this observational study needs further research to confirm the correlation between urolithiasis and MetS, and also the underlying mechanism.
urolithiasis, urinary tract stone, metabolic syndrome
Matsha TE, Hassan MS, Hon GM, Soita DJ, Kengne AP, Erasmus RT. Derivation and validation of a waist circumference optimal cutoff for diagnosing metabolic syndrome in a South African mixed ancestry population. Int J Cardiol. 2013; 168(3): 2954–5.
Samson SL, Garber AJ. Metabolic syndrome. Endocrinol Metab Clin North Am. 2014; 43(1): 1–23.
Gao WG, Qiao Q, Tuomilehto J, Balkau B, Ruotolo G, Calor G, et al. Does the constellation of risk factors with and without abdominal adiposity associate with different cardiovascular mortality risk? Int J Obes. 2008; 32(5): 757–62.
Ranasinghe P, Mathangasinghe Y, Jayawardena R, Hills AP, Misra A. Prevalence and trends of metabolic syndrome among adults in the Asia-pacific region: A systematic review. BMC Public Health. 2017; 17(1): 1–9.
Maalouf NM, Cameron MA, Moe OW, Adams-Huet B, Sakhaee K. Low urine pH: A novel feature of the metabolic syndrome. Clin J Am Soc Nephrol. 2007; 2(5): 883–8.
Liu YT, Yang PY, Yang YW, Sun HY, Lin IC. The association of nephrolithiasis with metabolic syndrome and its components: A cross-sectional analysis. Ther Clin Risk Manag. 2017; 13: 41–8.
Besiroglu H, Otunctemur A, Ozbek E. The metabolic syndrome and urolithiasis: A systematic review and meta-analysis. Ren Fail. 2015; 37(1): 1–6.
Deng T, Mai Z, Cai C, Duan X, Zhu W, Zhang T, et al. Influence of weight status on 24-hour urine composition in adults without urolithiasis: A nationwide study based on a Chinese Han population. PLoS One. 2017; 12(9): 1–10.
Yoshimura E, Sawada SS, Lee I-M, Gando Y, Kamada M, Matsushita M, et al. Body Mass Index and Kidney Stones: A Cohort Study of Japanese Men. J Epidemiol. 2016; 26(3): 131–6.
Denstedt JOHN, Khoury SAAD. Stone Disease. 2008. Available from: http://www.siu-urology.org/themes/web/assets/files/ICUD/pdf/Stone_Disease_2007.pdf
Lee Y-H, Huang W-C, Tsai J-Y, Lu C-Mi, Chen W-C, Lee M-H, et al. Epidemiological Studies on the Prevalence of Upper Urinary Calculi in Taiwan. 2013; 813: 1–37.
Daudon M, Lacour B, Jungers P. Influence of body size on urinary stone composition in men and women. Urol Res. 2006; 34(3): 193–9.
Knoll T, Schubert AB, Fahlenkamp D, Leusmann DB, Wendt-Nordahl G, Schubert G. Urolithiasis through the ages: Data on more than 200,000 urinary stone analyses. J Urol. 2011; 185(4): 1304–11.
Trinchieri A, Coppi F, Montanari E, Del Nero A, Zanetti G, Pisani E. Increase in the prevalence of symptomatic upper urinary tract stones during the last ten years. Eur Urol. 2000; 37(1): 23–5.
Trinchieri A, Croppi E, Montanari E. Obesity and urolithiasis: evidence of regional influences. Urolithiasis. 2017; 45(3): 271–8.
Inci M, Demirtas A, Sarli B, Akinsal E, Baydilli N. Association between body mass index, lipid profiles, and types of urinary stones. Ren Fail. 2012; 34(9): 1140–3.
Li WM, Chou YH, Li CC, Liu CC, Huang SP, Wu WJ, et al. Association of body mass index and urine pH in patients with urolithiasis. Urol Res. 2009; 37(4): 193–6.
Wein AJ, Kavoussi LR, Partin AW, Peters CA. Campbell-Walsh Urology. 2016.
Shadman A, Bastani B. Kidney Calculi. 2017; 11(3): 180–91.
Kovell LC, Ahmed HM, Misra S, Whelton SP, Prokopowicz GP, Blumenthal RS, et al. US hypertension management guidelines: A review of the recent past and recommendations for the future. J Am Heart Assoc. 2015; 4(12): 1–12.
Borghi L, Meschi T, Guerra A, Briganti A, Schianchi T, Allegri F, et al. Essential arterial hypertension and stone disease. Kidney Int. 1999; 55(6): 2397–406.
Cupisti A, D’Alessandro C, Samoni S, Meola M, Egidi MF. Nephrolithiasis and hypertension: possible links and clinical implications. J Nephrol. 2014; 27(5): 477–82.
Smith AD, Badlani GH, Preminger GM, Kavoussi LR. Smith’s Textbook of Endourology: 3rd Edition. Vols. 1–2, Smith’s Textbook of Endourology: 3rd Edition. 2012.
Keddis MT, Rule AD. Nephrolithiasis and loss of kidney function. Current Opinion in Nephrology and Hypertension. 2013.
Kittanamongkolchai W, Mara KC, Mehta RA, Vaughan LE, Denic A, Knoedler JJ, Enders FT, Lieske JC, Rule AD. Risk of hypertension among first-time symptomatic kidney stone formers. Clin J Am Soc Nephrol. 2017; 12(3): 476-482.
Masterson JH, Woo JR, Chang DC, Chi T, L’Esperance JO, Stoller ML, et al. Dyslipidemia is associated with an increased risk of nephrolithiasis. Urolithiasis. 2014; 43(1): 49–53.
Risk KS, Cesar F, Torricelli M, De SK, Gebreselassie S, Li I, et al. Dyslipidemia and Kidney Stone Risk. J Urol. 2014; 191(3): 667–72.
Kang HW, Seo SP, Kim WT, Kim Y, Yun S, Lee S, et al. Hypertriglyceridemia Is Associated With Increased Risk for Stone Recurrence in Patients With Urolithiasis. Urology. 2014; 84(4): 766–71.
Kirejczyk JK, Baran M, Porowska H, Porowski T, Wasilewska A. Dyslipidaemia in overweight children and adolescents is associated with an increased risk of kidney stones. 2015; 407–13.
PERKENI. Konsensus Pengendalian dan Pencegahan Diabetes Melitus Tipe 2 di Indonesia 2015. Perkeni; 2015. p. 78. Available from: http://pbperkeni.or.id/doc/konsensus.pdf.
Weinberg AE, Patel CJ, Chertow GM, Leppert JT. Diabetic severity and risk of kidney stone disease. Eur Urol. 2014; 65(1): 242–7.
Kabeya Y, Kato K, Tomita M, Katsuki T, Oikawa Y, Shimada A, et al. Associations of Insulin Resistance and Glycemic Control with the Risk of Kidney Stones. Intern Med. 2012; 51(7): 699–705.
Zhu W, Mai Z, Qin J, Duan X, Liu Y, Zhao Z, et al. Difference in 24-hour urine composition between diabetic and non-diabetic adults without nephrolithiasis. PLoS One. 2016; 11(2): 1–9.
Domingos F, Serra A. Metabolic syndrome: A multifaceted risk factor for kidney stones. Scand J Urol. 2014; 48(5): 414–9.
De Souza Filgueiras Pinto R, Almeida JR, Kang HC, Rosa MLG, Lugon JR. Metabolic syndrome and associated urolithiasis in adults enrolled in a community-based health program. Fam Pract. 2013; 30(3): 276–81.
Kummer AE, Grams M, Lutsey P, Chen Y, Matsushita K, Kottgen A, et al. Nephrolithiasis as a Risk Factor for CKD: The Atherosclerosis Risk in Communities Study. Clin J Am Soc Nephrol. 2015; 10(11): 2023–9.
Rendina D, De Filippo G, D’Elia L, Strazzullo P. Metabolic syndrome and nephrolithiasis: A systematic review and meta-analysis of the scientific evidence. J Nephrol. 2014; 27(4): 371–6.